Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million.

The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today’s order is thus the second order for NLAB Saga® from the customer, who primarily produces peptides including GLP-1 analogues.

“It is very pleasing that we are now taking a recurring order for NLAB Saga® from a customer. It confirms that the product works and is seen as a competitive alternative to our competitors’ products”, Nanologica’s CEO Andreas Bhagwani comments.

”Since the beginning of the year, we have been selling NLAB Saga®, i.e. silica for preparative chromatography, directly to end customers in China after we renegotiated the agreement with our distributor in China. This has been beneficial for us as we have been able to set up a dedicated team from Nanologica for sales of preparative silica in China, and we have a lower cost for our sales. The order we have now received is a result of the work that the team has done at the beginning of the year, and we look forward to the continued development in the Chinese market”, CEO Andreas Bhagwani continues.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

 

Links